Clinical Trial Update: Dasatinib in Advanced Non-small Cell Lung Cancer (NSCL) With Ex Vivo and In Vivo Assessment of Tumor Target Modulation [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating dasatinib in advanced non-small cell lung cancer; the study was terminated and results were posted in 2011.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Sprycel (dasatinib)

Snippet

Sponsor: H. Lee Moffitt Cancer Center and Research Institute | Conditions: Lung Cancer | Phase 2 | Status: TERMINATED | Results posted: 2011-09-07